219372
组织蛋白酶G抑制剂I
≥98% (HPLC), solid, cathepsin G inhibitor, Calbiochem®
别名:
组织蛋白酶G抑制剂I
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C36H33N2O6P
化学文摘社编号:
分子量:
620.63
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
产品名称
组织蛋白酶G抑制剂I, The Cathepsin G Inhibitor I, also referenced under CAS 429676-93-7, controls the biological activity of Cathepsin G. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
Quality Level
assay
≥98% (HPLC)
form
solid
potency
53 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 5 mg/mL, methanol: soluble
shipped in
ambient
storage temp.
−20°C
SMILES string
[P](=O)(O)(O)C(c5c6c(ccc5)cccc6)C(=O)c1cc2c(cc1C(=O)N(C3CCN(CC3)C(=O)c4ccccc4)C)cccc2
InChI
1S/C36H33N2O6P/c1-37(28-18-20-38(21-19-28)35(40)25-11-3-2-4-12-25)36(41)32-23-27-14-6-5-13-26(27)22-31(32)33(39)34(45(42,43)44)30-17-9-15-24-10-7-8-16-29(24)30/h2-17,22-23,28,34H,18-21H2,1H3,(H2,42,43,44)
InChI key
GNOZQRKYZJSIPZ-UHFFFAOYSA-N
General description
组织蛋白酶G的有效，选择性，可逆，竞争性非肽抑制剂[IC50=53 nM，Ki=63 nM]。弱抑制胰凝乳蛋白酶（Ki = 1.5 µM），弱抑制凝血酶，Xa因子，IXa因子，纤溶酶，胰蛋白酶，类胰蛋白酶，蛋白酶3和人白细胞弹性蛋白酶（IC50 >100 µM）。
组织蛋白酶G的有效，选择性，可逆，竞争性非肽抑制剂（IC50 = 53 nM，Ki = 63 nM）。弱抑制胰凝乳蛋白酶（Ki = 1.5 µM），对凝血酶，Xa因子，IXa因子，纤溶酶，胰蛋白酶，类胰蛋白酶，蛋白酶3和人白细胞弹性蛋白酶（IC50 >100 µM）没有任何明显的抑制作用。
Biochem/physiol Actions
靶标Ki：63 nM，对于组织蛋白酶G
细胞渗透性：否
产物不与ATP竞争。
可逆性：是
主要靶标
组织蛋白酶G
组织蛋白酶G
Packaging
用惰性气体包装
Preparation Note
复溶后，等分并冷冻（-20°C）。储备液在-20°C条件下可稳定保存3个月。
Other Notes
Greco, M.N., et al. 2002.J. Am. Chem. Soc.124, 3810.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：标准处理（A）
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Stefan J Schunk et al.
Circulation, 144(11), 893-908 (2021-07-02)
Cardiovascular diseases and chronic kidney disease (CKD) are highly prevalent, aggravate each other, and account for substantial mortality. Both conditions are characterized by activation of the innate immune system. The alarmin interleukin-1α (IL-1α) is expressed in a variety of cell
Akmaral Assylbekova et al.
Pharmaceuticals (Basel, Switzerland), 15(5) (2022-05-29)
Coronavirus disease 2019 (COVID-19) can lead to multi-organ failure influenced by comorbidities and age. Binding of the severe acute respiratory syndrome coronavirus 2 spike protein (SARS-CoV-2 S protein) to angiotensin-converting enzyme 2 (ACE2), along with proteolytic digestion of the S
Fabian Gärtner et al.
ACS omega, 5(43), 28233-28238 (2020-11-10)
During an immune response, cathepsin G (CatG) takes on the role of adaptive and innate immunity and the outcome depends on the localization of CatG. Soluble, cell surface-bound, or intracellular CatG is also responsible for pathophysiology conditions. We applied the
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 219372-1MG | 04055977202267 |
| 219372-5MG | 04055977202274 |